SeraNovo achieved excellent in vivo results improving the bioavailability of itraconazole by more than 230% compared to the best commercial formulation. Itraconazole is a notorious drug molecule because it is so poorly soluble and subsequently poorly bioavailable. To prove our technology, we designed a new itraconazole formulation. After excellent in vitro results, we commissioned a CRO to complete a comparative in vivo study between our formulation and the best commercial formulation. This evidence of efficacy has generated significant commercial interest.